Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.
Ishida M, Morimoto K, Yamada T, Shiotsu S, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Takeda T, Takayama K. Ishida M, et al. Among authors: morimoto y, morimoto k. Thorac Cancer. 2022 Jan;13(2):173-181. doi: 10.1111/1759-7714.14236. Epub 2021 Nov 17. Thorac Cancer. 2022. PMID: 34791812 Free PMC article.
Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients.
Morimoto K, Yamada T, Nakamura R, Katayama Y, Tanaka S, Takumi C, Hiraoka N, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: morimoto y. Med Oncol. 2020 Nov 11;37(12):111. doi: 10.1007/s12032-020-01440-3. Med Oncol. 2020. PMID: 33175248
Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study.
Morimoto K, Yamada T, Takumi C, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: morimoto y. Front Oncol. 2021 Mar 23;11:630136. doi: 10.3389/fonc.2021.630136. eCollection 2021. Front Oncol. 2021. PMID: 33833990 Free PMC article.
Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: morimoto y. Oncoimmunology. 2021 Jul 8;10(1):1950411. doi: 10.1080/2162402X.2021.1950411. eCollection 2021. Oncoimmunology. 2021. PMID: 34290909 Free PMC article.
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Morimoto K, et al. Among authors: morimoto y. Lung Cancer. 2021 Nov;161:26-33. doi: 10.1016/j.lungcan.2021.08.015. Epub 2021 Aug 31. Lung Cancer. 2021. PMID: 34500218
Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Morimoto K, et al. Among authors: morimoto y. J Cancer Res Clin Oncol. 2022 Sep;148(9):2437-2446. doi: 10.1007/s00432-021-03782-5. Epub 2021 Sep 12. J Cancer Res Clin Oncol. 2022. PMID: 34510271
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
Tanimura K, Yamada T, Horinaka M, Katayama Y, Fukui S, Morimoto K, Nakano T, Tokuda S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Yoneda K, Yano S, Sakai T, Takayama K. Tanimura K, et al. Among authors: morimoto y, morimoto k. Cancer Lett. 2021 Dec 1;522:119-128. doi: 10.1016/j.canlet.2021.09.018. Epub 2021 Sep 15. Cancer Lett. 2021. PMID: 34534615
Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
Nakamura R, Yamada T, Morimoto K, Nakao A, Goto Y, Ogura Y, Takeda T, Takumi C, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Tanaka S, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Uchino J, Takayama K. Nakamura R, et al. Among authors: morimoto y, morimoto k. J Cancer Res Clin Oncol. 2022 Nov;148(11):2985-2994. doi: 10.1007/s00432-021-03866-2. Epub 2021 Nov 26. J Cancer Res Clin Oncol. 2022. PMID: 34825950
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.
Katayama Y, Yamada T, Tokuda S, Okura N, Nishioka N, Morimoto K, Tanimura K, Morimoto Y, Iwasaku M, Horinaka M, Sakai T, Kita K, Yano S, Takayama K. Katayama Y, et al. Among authors: morimoto y, morimoto k. Cancer Med. 2022 Feb;11(4):944-955. doi: 10.1002/cam4.4504. Epub 2022 Jan 14. Cancer Med. 2022. PMID: 35029047 Free PMC article.
2,268 results